Tradestie Institutional Equity Comparison Engine

OCUL vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while OCUL counters with relative strength in Growth & Margin. Fundamentally, OCUL trades at N/M Forward P/E with -680.9% operating margin (-11.5% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, OCUL sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
OCUL N/M vs ZBIO N/M Fwd P/E
Growth & Margin Winner OCUL
Op Margin -680.9% vs -2747.5% ยท YoY -11.5% vs -100.0%
Momentum & Technical Winner ZBIO
1Y -46.3% vs -21.7% ยท 52W Pos 1% vs 46%
Options & Structure Winner ZBIO
BREAKDOWN (7th %ile IV) vs CONSOLIDATION (13th %ile IV)
OCUL NASDAQ
Ocular Therapeutix, Inc.
Pharmaceutical Preparations
$6.01
-3.22% 1D
Market Cap $1.4B
1M Return -12.52%
1Y Return -46.29%
Forward P/E N/M
Unified AI Score
45.2 / 100 HOLD
Tech 19.0 Fund 47.0 Flow 69.0 Mom 64.9
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OCUL -46.29% ZBIO -21.68% Spread: +24.61 pp (ZBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OCUL Revenue ZBIO Revenue OCUL Op. Margin ZBIO Op. Margin Margin Edge
FY2018 $0M N/A -2970.8% N/A OCUL
FY2019 $0M N/A -2029.9% N/A OCUL
FY2020 $20M N/A -361.1% N/A OCUL
FY2021 $40M N/A -179.3% N/A OCUL
FY2022 $50M N/A -152.7% N/A OCUL
FY2023 $60M $50M -141.0% -74.3% ZBIO
FY2024 $60M $10M -269.6% -3277.8% OCUL
FY2025 $50M $10M -519.8% -3830.6% OCUL

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OCUL (3) vs ZBIO (4)
Institutional Metric OCUL ZBIO Criterion Row Winner
Market Capitalization Scale $1.4B $1.9B Larger Scale ZBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -11.5% -100.0% Higher Growth OCUL
Operating Margin (TTM) Profitability -680.9% -2747.5% Higher Margin OCUL
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -93.5% -265.1% Higher ROE OCUL
52-Week Range Position Momentum 1% ($6โ€“$16) 46% ($14โ€“$45) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.69ฮฒ ยท 68% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk ZBIO
Unified Institutional Score Composite Signal 45.2 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OCUL vs ZBIO Buy Guide
OCUL BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live OCUL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OCUL nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.